Working Toward A Cure: Janssen’s Multiple Myeloma Strategy

Multiple myeloma is all about combination regimens, but Janssen Pharmaceutical Cos. is bringing forward new therapies with promising single-agent activity with the goal of shaking up existing regimens and curing patients early in their disease. Mark Wildgust, vice president of global medical affairs in Janssen’s oncology group, explained to Scrip how the Johnson & Johnson subsidiary is building on its success with the CD38 inhibitor Darzalex (daratumumab) with curative regimens in mind.

Darzalex and its subcutaneously administered version Darzalex Faspro are approved in six different multiple myeloma indications, including as a monotherapy in the fourth line or later and in combination with various standard-of-care drugs in newly diagnosed autologous stem cell transplant-ineligible and transplant-eligible patients